Find therapies in clinical trials near you – page 10

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Effect of Follitropin Delta plus Menotrophin on Embryo Quality in Advanced Age Women with Infertility

Effect of Follitropin Delta plus Menotrophin on Embryo Quality in Advanced Age Women with Infertility

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Study of Disitamab Vedotin alone or with Pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

Study of Disitamab Vedotin alone or with Pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Study Comparing Teriparatide and Alendronate for Preventing Bone Fractures in Women Over 65 with Fragile Bones